Navigation Links
Gentech Pharmaceutical Appoints New Medical Director for PhenTabz/ADDTabz
Date:5/22/2012

FORT MYERS, Fla., May 22, 2012 /PRNewswire-iReach/ -- Gentech Pharmaceutical announced today that Dr. Stan Headley has joined the company as Medical Director for its' PhenTabz and ADDTabz products. Dr. Headley brings over 15 years of experience to the world of Integrative Medicine. He holds a Doctorate of Medicine from Spartan Health Science University with clinical training in family medicine at Creighton University School of Medicine and St. Joseph's Hospital in Omaha, Nebraska.

Dr. Headley has served in various capacities in Natural Health as a clinical family medicine practitioner, Chief Medical Officer, Medical Director, Clinical Operations Manager, Natural Products Researcher, Product Training Educator and advocate as a guest speaker on various radio and television programs on Natural Health forums including International radio programs in Puerto Rico and Barbados.

"Dr. Headley's wealth of experience and industry knowledge has already made him a key addition to the Gentech Pharmaceutical family. We are extremely excited to have him as our Medical Director as we continue to grow. Our current products PhenTabz and ADDtabz and new innovations currently in development, paired with increasing demand from our customers led us to look for a skilled professional who understood the incredible opportunities in the field of designer pharmacological alternatives. We have found that professional in Dr. Stan Headley.", says Derek Vest, CEO.

About Gentech Pharmaceutical
Gentech Pharmaceutical applies the science of perfecting and improving current medications and OTC formulations/chemical structures to produce "designer pharmacological alternatives" without the side effects. This unique ability allows Gentech Pharmaceutical to produce the most therapeutically advanced and safe pharmacological products currently available. Gentech shares the most basic and sacred goals of the physicians whom they provide products to: improve the health and well-being of patients with the safest and most effective products available in PhenTabz and ADDTabz.

Press release submitted by SubmitPressRelease123.com

Media Contact: Mike Sharp Gentech Pharmaceutical, 888-666-1714, marketing@gentechpharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Gentech Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Globe Awards Adds Gentech Pharmaceutical as New Participating Sponsor
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... British Columbia , December 2, 2016 - bioLytical lanza ... las nuevas directrices de la OMS     Continue Reading ... ... , , ... de enfermedades infecciosas, ha anunciado hoy que está expandiendo el lanzamiento de su ...
(Date:12/2/2016)... , December 2, 2016 Persistence ... pacemaker market in its upcoming report titled, "Global Market Study on ... Declining CAGR of -1.4% between 2016 and 2024". The global ... in 2015 and this is likely to decline to ... the global cardiac pacemaker market is anticipated to exhibit ...
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary device ... in the Emergency Response Training and Support Services (ERTSS) ... to have LifeVac become part of the ERTSS mission ... and CEO of LifeVac. "Having an established network of ... effectively will help leverage our efforts to spread LifeVac,s ...
Breaking Medicine Technology:
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a secure, cloud-based ... named the best Sales Team of 2016 as part of the 2016 SIIA ... the Software & Information Industry Association (SIIA), the principal trade association for the ...
(Date:11/30/2016)... ... 2016 , ... "I hate when the mixture of saliva and toothpaste runs ... inventor from Bridgewater, N.J. "I thought that there had to be a way to ... the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle ...
Breaking Medicine News(10 mins):